Who are Travoprost/timolol therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Drug: latanoprost/timolol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/travoprost-timolol-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Travoprost/timolol therapy — Competitive Intelligence Brief

Travoprost/timolol therapy (Travoprost/timolol therapy) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analog/beta-blocker combination. Area: Ophthalmology.

marketed Prostaglandin analog/beta-blocker combination Prostaglandin F receptor (FP receptor) and beta-adrenergic receptors (beta-1 and beta-2) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Travoprost/timolol therapy (Travoprost/timolol therapy) — Aristotle University Of Thessaloniki. Travoprost/timolol is a fixed-dose combination that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor (travoprost) and decreasing aqueous humor production (timolol).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Travoprost/timolol therapy TARGET	Travoprost/timolol therapy	Aristotle University Of Thessaloniki	marketed	Prostaglandin analog/beta-blocker combination	Prostaglandin F receptor (FP receptor) and beta-adrenergic receptors (beta-1 and beta-2)
Drug: latanoprost/timolol	Drug: latanoprost/timolol	Aristotle University Of Thessaloniki	marketed	Prostaglandin analog/beta-blocker combination	Prostaglandin F receptor (FP receptor) and beta-adrenergic receptors (β1 and β2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analog/beta-blocker combination class)

Aristotle University Of Thessaloniki · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Travoprost/timolol therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/travoprost-timolol-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab